Jasper Therapeutics Seeks Stockholder Approval for Reverse Split and Share Increase to Avoid Nasdaq Delisting
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.2× avg).
Summary
Jasper Therapeutics filed a preliminary proxy seeking stockholder approval for a reverse stock split (1-for-15 to 1-for-35) to regain Nasdaq compliance and an increase in authorized shares to satisfy the Kira merger agreement. The special meeting is set for September 30, 2026.
Key Events · Corporate Governance and Compliance · JSPR
-
Reverse Stock Split Proposed
Board seeks approval for a reverse split between 1-for-15 and 1-for-35, at its discretion, on or before December 31, 2026, to raise the stock price above the $1.00 Nasdaq minimum bid requirement.
-
Nasdaq Delisting Risk
Stock closed at $0.716 on August 21, 2026, below the $1.00 minimum. The company has until November 30, 2026 to regain compliance or face delisting proceedings.
-
Authorized Share Increase
Proposal to increase authorized common shares from 490 million to 675 million, required by the Kira merger agreement to permit conversion of 9,555,390 preferred shares (each convertible into 61 common shares).
-
Special Meeting Scheduled
Stockholders will vote on September 30, 2026, with a record date of August 10, 2026. As of the record date, 33,274,561 common shares were outstanding.
Analysis · JSPR · Life Sciences
Jasper Therapeutics is asking stockholders to approve a reverse stock split of up to 1-for-35 and an increase in authorized shares from 490 million to 675 million. The reverse split is a direct response to the Nasdaq minimum bid price deficiency — the stock closed at $0.716 on August 21, 2026, well below the $1.00 requirement, with a November 30, 2026 compliance deadline. The authorized share increase is required by the July 2026 Kira Pharmaceuticals merger agreement to permit conversion of the preferred stock issued in that deal. If the reverse split fails, the company faces delisting to the OTC market, which would severely impair liquidity and its ability to raise capital. The proposals are independent — the Board may implement one without the other — but both are critical to the company's survival as a listed entity.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 37.5% of the 3362 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24M. The 52-week trading range was $0.32 to $3.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.